VYNE Therapeutics 2023 Investor Presentation

VYNE Therapeutics is developing a pipeline of BET inhibitor candidates to address unmet needs in inflammatory and immunology conditions. The presentation outlines the company's clinical programs including VYN201 for vitiligo, VYN202 for conditions like rheumatoid arthritis and lupus, and exclusive access to a library of BET inhibitor candidates. VYNE had cash runway guidance into Q4 2023 based on current development activities.